263 related articles for article (PubMed ID: 37507721)
1. Differential risks of syringe service program participants in Central Ohio: a latent class analysis.
Moon KJ; Bryant I; Trinh A; Hasenstab KA; Carter B; Barclay R; Nawaz S
Harm Reduct J; 2023 Jul; 20(1):97. PubMed ID: 37507721
[TBL] [Abstract][Full Text] [Related]
2. Examining risk behavior and syringe coverage among people who inject drugs accessing a syringe services program: A latent class analysis.
Bartholomew TS; Tookes HE; Bullock C; Onugha J; Forrest DW; Feaster DJ
Int J Drug Policy; 2020 Apr; 78():102716. PubMed ID: 32146348
[TBL] [Abstract][Full Text] [Related]
3. Association of Injection Practices and Overdose With Drug Use Typologies: A Latent Class Analysis Among People Who Inject Drugs in Baltimore, 2017.
Gicquelais RE; Genberg BL; Astemborski J; Celentano DD; Kirk GD; Mehta SH
AIDS Educ Prev; 2019 Aug; 31(4):344-362. PubMed ID: 31361518
[TBL] [Abstract][Full Text] [Related]
4. Injection and Sexual Behavior Profiles among People Who Inject Drugs in Miami, Florida.
Chueng TA; Tookes HE; McLaughlin M; Arcaro-Vinas AM; Serota DP; Bartholomew TS
Subst Use Misuse; 2022; 57(9):1374-1382. PubMed ID: 35686722
[TBL] [Abstract][Full Text] [Related]
5. Substance-use and sexual harm reduction strategies of methamphetamine-using men who have sex with men and inject drugs.
Wilkerson JM; Noor SW; Breckenridge ED; Adeboye AA; Rosser BR
AIDS Care; 2015; 27(8):1047-54. PubMed ID: 25837492
[TBL] [Abstract][Full Text] [Related]
6. Latent classes of polydrug and polyroute use and associations with human immunodeficiency virus risk behaviours and overdose among people who inject drugs in Tijuana, Baja California, Mexico.
Meacham MC; Roesch SC; Strathdee SA; Lindsay S; Gonzalez-Zuniga P; Gaines TL
Drug Alcohol Rev; 2018 Jan; 37(1):128-136. PubMed ID: 28337798
[TBL] [Abstract][Full Text] [Related]
7. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs.
Allen ST; Grieb SM; O'Rourke A; Yoder R; Planchet E; White RH; Sherman SG
Harm Reduct J; 2019 May; 16(1):33. PubMed ID: 31109339
[TBL] [Abstract][Full Text] [Related]
8. Unmet needs and harm reduction preferences of syringe services program participants: differences by co-use of illicit opioids and methamphetamine.
Sun R; Sauda TH; Hoopsick RA
Harm Reduct J; 2024 Jun; 21(1):119. PubMed ID: 38890736
[TBL] [Abstract][Full Text] [Related]
9. Polydrug Use and Heterogeneity in HIV Risk Among People Who Inject Drugs in Estonia and Russia: A Latent Class Analysis.
Tavitian-Exley I; Boily MC; Heimer R; Uusküla A; Levina O; Maheu-Giroux M
AIDS Behav; 2018 Apr; 22(4):1329-1340. PubMed ID: 28699018
[TBL] [Abstract][Full Text] [Related]
10. Syringe sharing among people who inject drugs in London, Canada.
Scheim AI; Bardwell G; Rachlis B; Mitra S; Kerr T
Can J Public Health; 2018 Apr; 109(2):174-182. PubMed ID: 29981046
[TBL] [Abstract][Full Text] [Related]
11. Baseline prevalence and correlates of HIV and HCV infection among people who inject drugs accessing a syringe services program; Miami, FL.
Bartholomew TS; Onugha J; Bullock C; Scaramutti C; Patel H; Forrest DW; Feaster DJ; Tookes HE
Harm Reduct J; 2020 Jun; 17(1):40. PubMed ID: 32522201
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017).
Scheibe A; Young K; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Puren A; Hausler H
BMC Infect Dis; 2020 Sep; 20(1):655. PubMed ID: 32894072
[TBL] [Abstract][Full Text] [Related]
13. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
14. Promoting Safe Injection Practices, Substance Use Reduction, Hepatitis C Testing, and Overdose Prevention Among Syringe Service Program Clients Using a Computer-Tailored Intervention: Pilot Randomized Controlled Trial.
Hochstatter KR; Hull SJ; Sethi AK; Burns ME; Mundt MP; Westergaard RP
J Med Internet Res; 2020 Sep; 22(9):e19703. PubMed ID: 32990630
[TBL] [Abstract][Full Text] [Related]
15. Patterns of drug use, risky behavior, and health status among persons who inject drugs living in San Diego, California: a latent class analysis.
Roth AM; Armenta RA; Wagner KD; Roesch SC; Bluthenthal RN; Cuevas-Mota J; Garfein RS
Subst Use Misuse; 2015 Jan; 50(2):205-14. PubMed ID: 25313832
[TBL] [Abstract][Full Text] [Related]
16. Substance use patterns, sociodemographics, and health profiles of harm reduction service recipients in Burlington, Vermont.
Erath TG; LaCroix R; O'Keefe E; Higgins ST; Rawson RA
Harm Reduct J; 2024 Apr; 21(1):76. PubMed ID: 38580997
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and risk factors associated with HIV/hepatitis B and HIV/hepatitis C co-infections among people who inject drugs in Mozambique.
Semá Baltazar C; Boothe M; Kellogg T; Ricardo P; Sathane I; Fazito E; Raymond HF; Temmerman M; Luchters S
BMC Public Health; 2020 Jun; 20(1):851. PubMed ID: 32493347
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree.
Ijioma SC; Pontinha VM; Holdford DA; Carroll NV
J Manag Care Spec Pharm; 2021 Feb; 27(2):137-146. PubMed ID: 33506729
[No Abstract] [Full Text] [Related]
19. Hepatitis C and HIV incidence and harm reduction program use in a conflict setting: an observational cohort of injecting drug users in Kabul, Afghanistan.
Todd CS; Nasir A; Stanekzai MR; Fiekert K; Sipsma HL; Vlahov D; Strathdee SA
Harm Reduct J; 2015 Oct; 12():22. PubMed ID: 26472126
[TBL] [Abstract][Full Text] [Related]
20. Health outcomes and cost-effectiveness of diversion programs for low-level drug offenders: A model-based analysis.
Bernard CL; Rao IJ; Robison KK; Brandeau ML
PLoS Med; 2020 Oct; 17(10):e1003239. PubMed ID: 33048929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
